Steven Mah
Stock Analyst at TD Cowen
(2.25)
# 2,684
Out of 5,180 analysts
29
Total ratings
37.93%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $43.26 | +34.07% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $18.78 | +65.07% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $5.48 | +2,089.78% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $2.84 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $11.07 | +279.40% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.28 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.56 | +541.03% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.76 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $1.54 | +1,263.64% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $186.84 | -17.04% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $15.63 | +795.71% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.26 | +4,026.98% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $120.81 | +243.51% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $15.26 | +1,538.27% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $43.26
Upside: +34.07%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $18.78
Upside: +65.07%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $5.48
Upside: +2,089.78%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $2.84
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $11.07
Upside: +279.40%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.28
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.56
Upside: +541.03%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.76
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $1.54
Upside: +1,263.64%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $186.84
Upside: -17.04%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $15.63
Upside: +795.71%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.26
Upside: +4,026.98%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $120.81
Upside: +243.51%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $15.26
Upside: +1,538.27%